Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
Récher C, Dumas PY, Bérard E, Tavitian S, Leguay T, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Luquet I, Klein E, de Grande AC, Sarry A, Zukunft S, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M, Serve H, Bertoli S, Pigneux A, Röllig C. Récher C, et al. Among authors: vergez f. Am J Hematol. 2025 Jan;100(1):23-32. doi: 10.1002/ajh.27510. Epub 2024 Nov 18. Am J Hematol. 2025. PMID: 39555737 Free PMC article.
Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
Jeanselme P, Tavitian S, Lapierre L, Vergez F, Rigolot L, Huynh A, Bertoli S, Delabesse E, Huguet F. Jeanselme P, et al. Among authors: vergez f. Leuk Lymphoma. 2024 Dec;65(13):2025-2030. doi: 10.1080/10428194.2024.2390572. Epub 2024 Aug 14. Leuk Lymphoma. 2024. PMID: 39141583 Review.
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, Récher C. Garciaz S, et al. Among authors: vergez f. Am J Hematol. 2024 Oct;99(10):1870-1876. doi: 10.1002/ajh.27417. Epub 2024 Jun 20. Am J Hematol. 2024. PMID: 38899566
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, Facon T. Leleu X, et al. Among authors: vergez f. Nat Med. 2024 Aug;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830994 Free PMC article. Clinical Trial.
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C, Dumas PY, Bérard E, Bidet A, Delabesse E, Tavitian S, Leguay T, Huguet F, Borel C, Forcade E, Vergez F, Vial JP, Rieu JB, Lechevalier N, Luquet I, Canali A, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C, Largeaud L, Bertoli S. Gondran C, et al. Among authors: vergez f. Blood Cancer J. 2024 May 31;14(1):91. doi: 10.1038/s41408-024-01069-9. Blood Cancer J. 2024. PMID: 38821940 Free PMC article.
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.
Dussiau C, Comont T, Knosp C, Vergnolle I, Bravetti C, Canali A, Houvert A, Largeaud L, Daveaux C, Zaroili L, Friedrich C, Boussaid I, Zalmai L, Almire C, Rauzy O, Willems L, Birsen R, Bouscary D, Fontenay M, Kosmider O, Chapuis N, Vergez F. Dussiau C, et al. Among authors: vergez f. Leukemia. 2024 May;38(5):1131-1142. doi: 10.1038/s41375-024-02234-6. Epub 2024 Apr 4. Leukemia. 2024. PMID: 38575672 Free PMC article.
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Didi I, Alliot JM, Dumas PY, Vergez F, Tavitian S, Largeaud L, Bidet A, Rieu JB, Luquet I, Lechevalier N, Delabesse E, Sarry A, De Grande AC, Bérard E, Pigneux A, Récher C, Simoncini D, Bertoli S. Didi I, et al. Among authors: vergez f. Leuk Res. 2024 Jan;136:107437. doi: 10.1016/j.leukres.2024.107437. Epub 2024 Jan 9. Leuk Res. 2024. PMID: 38215555 Free article.
Vitamin C and D supplementation in acute myeloid leukemia.
Mouchel PL, Bérard E, Tavitian S, Gadaud N, Vergez F, Rieu JB, Luquet I, Sarry A, Huguet F, Largeaud L, Delabesse E, Huynh A, Bertoli S, Récher C. Mouchel PL, et al. Among authors: vergez f. Blood Adv. 2023 Nov 28;7(22):6886-6897. doi: 10.1182/bloodadvances.2023010559. Blood Adv. 2023. PMID: 37671973 Free PMC article.
98 results